Wuxi Biologics
Wuxi Biologics, officially known as WuXi AppTec Co., Ltd., is a leading global contract research, development, and manufacturing organisation (CDMO) headquartered in Wuxi, China. Founded in 2010, the company has rapidly expanded its operations across major regions, including the United States and Europe, establishing itself as a key player in the biopharmaceutical industry. Specialising in biologics, Wuxi Biologics offers a comprehensive range of services, from cell line development to commercial manufacturing. Their unique integrated platform streamlines the drug development process, enabling clients to bring innovative therapies to market more efficiently. With a strong commitment to quality and innovation, Wuxi Biologics has achieved significant milestones, including numerous partnerships with leading pharmaceutical companies, solidifying its position as a trusted partner in the global biopharmaceutical landscape.
DitchCarbon Score
How does Wuxi Biologics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Wuxi Biologics's score of 52 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Wuxi Biologics's reported carbon emissions
In 2024, Wuxi Biologics reported total greenhouse gas emissions of approximately 198,654,000 kg CO2e, comprising 38,346,000 kg CO2e from Scope 1 and 160,308,000 kg CO2e from Scope 2 emissions. Additionally, Scope 3 emissions included 24,700,000 kg CO2e from business travel, 19,176,000 kg CO2e from employee commuting, and 39,468,000 kg CO2e from fuel and energy-related activities, among others. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emission intensity by 50% by 2030, using 2020 as the baseline year. This target reflects Wuxi Biologics' commitment to sustainability and aligns with industry standards for reducing carbon footprints. Wuxi Biologics is also committed to achieving net-zero emissions across all scopes by 2050, demonstrating a long-term dedication to climate action. The company’s proactive approach to emissions reduction and sustainability positions it as a responsible leader in the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,042,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,361,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Wuxi Biologics is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
